Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
Age-related macular degeneration
Anti-VEGF
Macular neovascularization
Non-resolving
Subretinal fluid
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
25
06
2020
accepted:
20
11
2020
revised:
01
10
2020
pubmed:
28
11
2020
medline:
19
8
2021
entrez:
27
11
2020
Statut:
ppublish
Résumé
To describe the clinical characteristics and visual outcomes of neovascular age-related macular degeneration (NV-AMD) patients with irregular pigment epithelium detachment (PED) and non-resolving subretinal fluid (SRF) despite continuous monthly injections of anti-vascular endothelial growth factor (VEGF). This is a retrospective case series, including NV-AMD patients treated in a tertiary academic practice. Inclusion criteria were NV-AMD diagnosis, with irregular PED, and non-resolving SRF treated with continuous monthly anti-VEGF intravitreal injections. Data collection included best corrected visual acuity (BCVA), central macular thickness (CMT), sub-foveal choroidal thickness (SFCT), and type and location of PED as seen on optical coherence tomography (OCT). A total of 738 patients with NV-AMD underwent anti-VEGF injections during the follow-up period and 20 eyes of 19 patients (14 females and 5 males) met the inclusion criteria. Average age was 81.7 ± 6.6 years, mean follow-up time was 32.1 ± 23.5 months, and mean number of injections was 31.3 ± 24.2. Mean VA was 0.26 ± 0.21 logMAR (Snellen 20/36) at baseline versus 0.20 ± 0.23 logMAR (Snellen 20/32) at the end of the follow-up (P = 0.28). All eyes presented with sub-foveal, type 1 macular neovascularization (MNV). Average sub-foveal choroidal thickness changed from 189.70 ± 68.46 μm at baseline to 169.00 ± 63.06 μm (P < 0.001) at last follow-up. Patients with type 1 NV-AMD, irregular PED, and non-resolving SRF and under continuous treatment of monthly anti-VEGF injections may maintain good visual acuity after long period of time.
Identifiants
pubmed: 33245430
doi: 10.1007/s00417-020-05024-9
pii: 10.1007/s00417-020-05024-9
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1153-1160Références
Lim LS, Mitchell P, Seddon JM et al (2012) Age-related macular degeneration. Lancet 379:1728–1738. https://doi.org/10.1016/S0140-6736(12)60282-7
doi: 10.1016/S0140-6736(12)60282-7
pubmed: 22559899
Jonas JB, Cheung CMG, Panda-Jonas S (2017) Updates on the epidemiology of age-related macular degeneration. Asia-Pacific J Ophthalmol 6:493–497. https://doi.org/10.22608/APO.2017251
doi: 10.22608/APO.2017251
Spaide RF (2017) Choroidal neovascularization. Retina 37:609–610. https://doi.org/10.1097/IAE.0000000000001575
doi: 10.1097/IAE.0000000000001575
pubmed: 28207610
Spaide RF, Jaffe GJ, Sarraf D et al (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology 127:616–636. https://doi.org/10.1016/j.ophtha.2019.11.004
doi: 10.1016/j.ophtha.2019.11.004
pubmed: 31864668
pmcid: 31864668
Domalpally A, Clemons TE, Bressler SB et al (2019) Imaging characteristics of choroidal neovascular lesions in the AREDS2-HOME study: report number 4. Ophthalmol Retin 3:326–335. https://doi.org/10.1016/j.oret.2019.01.004
doi: 10.1016/j.oret.2019.01.004
Grossniklaus HE, Gass JD (1998) Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 126:59–69. https://doi.org/10.1016/s0002-9394(98)00145-7
doi: 10.1016/s0002-9394(98)00145-7
pubmed: 9683150
Freund KB, Ho I-V, Barbazetto IA et al (2008) Type 3 neovascularization. Retina 28:201–211. https://doi.org/10.1097/IAE.0b013e3181669504
doi: 10.1097/IAE.0b013e3181669504
pubmed: 18301024
Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481
doi: 10.1056/NEJMoa054481
pubmed: 17021318
Jaffe GJ, Martin DF, Toth CA et al (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120:1860–1870. https://doi.org/10.1016/j.ophtha.2013.01.073
doi: 10.1016/j.ophtha.2013.01.073
pubmed: 23642377
pmcid: 3737287
Gianniou C, Dirani A, Jang L, Mantel I (2015) Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab. Retina 35:1195–1201. https://doi.org/10.1097/IAE.0000000000000465
doi: 10.1097/IAE.0000000000000465
pubmed: 25650710
Cohen SY, Creuzot-Garcher C, Darmon J et al (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173–1176. https://doi.org/10.1136/bjo.2007.115501
doi: 10.1136/bjo.2007.115501
pubmed: 17383997
pmcid: 1954889
Gillies MC, Campain A, Barthelmes D et al (2015) Long-term outcomes of treatment of neovascular age-related macular degeneration. Ophthalmology 122:1837–1845. https://doi.org/10.1016/j.ophtha.2015.05.010
doi: 10.1016/j.ophtha.2015.05.010
pubmed: 26096346
Rao P, Lum F, Wood K et al (2018) Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS Registry. Ophthalmology 125:522–528. https://doi.org/10.1016/j.ophtha.2017.10.010
doi: 10.1016/j.ophtha.2017.10.010
pubmed: 29146306
Maguire MG, Martin DF, Ying G et al (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Ophthalmology 123:1751–1761. https://doi.org/10.1016/j.ophtha.2016.03.045
doi: 10.1016/j.ophtha.2016.03.045
pubmed: 27156698
pmcid: 27156698
Bhavsar KV, Freund KB (2014) Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol Off J Saudi Ophthalmol Soc 28:129–133. https://doi.org/10.1016/j.sjopt.2014.03.001
doi: 10.1016/j.sjopt.2014.03.001
Jang L, Gianniou C, Ambresin A, Mantel I (2015) Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. Graefes Arch Clin Exp Ophthalmol 253:1211–1216. https://doi.org/10.1007/s00417-014-2789-x
doi: 10.1007/s00417-014-2789-x
pubmed: 25267418
Wang J-S, Kefalov VJ (2011) The cone-specific visual cycle. Prog Retin Eye Res 30:115–128. https://doi.org/10.1016/j.preteyeres.2010.11.001
doi: 10.1016/j.preteyeres.2010.11.001
pubmed: 21111842
Shin JW, Shin YU, Cho HY, Lee BR (2012) Measurement of choroidal thickness in normal eyes using 3D OCT-1000 spectral domain optical coherence tomography. Korean J Ophthalmol 26:255. https://doi.org/10.3341/kjo.2012.26.4.255
doi: 10.3341/kjo.2012.26.4.255
pubmed: 22870023
pmcid: 3408529
Manjunath V, Taha M, Fujimoto JG, Duker JS (2010) Choroidal thickness in normal eyes measured using cirrus HD optical coherence tomography. Am J Ophthalmol 150:325–329.e1. https://doi.org/10.1016/j.ajo.2010.04.018
doi: 10.1016/j.ajo.2010.04.018
pubmed: 20591395
pmcid: 2926223
Kuroda S, Ikuno Y, Yasuno Y et al (2013) Choroidal thickness in central serous chorioretinopathy. Retina 33:302–308. https://doi.org/10.1097/IAE.0b013e318263d11f
doi: 10.1097/IAE.0b013e318263d11f
pubmed: 23064424
Chung SE, Kang SW, Lee JH, Kim YT (2011) Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration. Ophthalmology 118:840–845. https://doi.org/10.1016/j.ophtha.2010.09.012
doi: 10.1016/j.ophtha.2010.09.012
pubmed: 21211846
Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003
doi: 10.1016/j.preteyeres.2015.05.003
pubmed: 26026923
Willoughby AS, Ying GS, Toth CA et al (2015) Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology 122:1846–1853.e5. https://doi.org/10.1016/j.ophtha.2015.05.042
doi: 10.1016/j.ophtha.2015.05.042
pubmed: 26143666
pmcid: 4549177
Shah VP, Shah SA, Mrejen S, Freund KB (2014) Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration. Retina 34:1281–1288. https://doi.org/10.1097/IAE.0000000000000166
doi: 10.1097/IAE.0000000000000166
pubmed: 24695062
Berg K, Pedersen TR, Sandvik L, Bragadóttir R (2015) Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 122:146–152. https://doi.org/10.1016/j.ophtha.2014.07.041
doi: 10.1016/j.ophtha.2014.07.041
pubmed: 25227499
Richard G, Monés J, Wolf S et al (2015) Scheduled versus pro re Nata dosing in the VIEW trials. Ophthalmology 122:2497–2503. https://doi.org/10.1016/j.ophtha.2015.08.014
doi: 10.1016/j.ophtha.2015.08.014
pubmed: 26477840
Wykoff CC, Croft DE, Brown DM et al (2015) Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration. Ophthalmology 122:2514–2522. https://doi.org/10.1016/j.ophtha.2015.08.009
doi: 10.1016/j.ophtha.2015.08.009
pubmed: 26391465
Chakravarthy U, Bezlyak V, Sagkriotis A et al (2019) Effectiveness of continued ranibizumab therapy in neovascular age-related macular degeneration versus switch to aflibercept: real world evidence. Ophthalmol Retin 3:8–15.e1. https://doi.org/10.1016/j.oret.2018.09.001
doi: 10.1016/j.oret.2018.09.001
Mimouni M, Meshi A, Vainer I et al (2018) Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Jpn J Ophthalmol 62:652–658. https://doi.org/10.1007/s10384-018-0619-0
doi: 10.1007/s10384-018-0619-0
pubmed: 30269186
Brown DM, Chen E, Mariani A et al (2013) Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration–primary end point. Ophthalmology 120:349–354. https://doi.org/10.1016/j.ophtha.2012.08.008
doi: 10.1016/j.ophtha.2012.08.008
pubmed: 23131717
Lois N, McBain V, Abdelkader E et al (2013) Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Retina 33:13–22. https://doi.org/10.1097/IAE.0b013e3182657fff
doi: 10.1097/IAE.0b013e3182657fff
pubmed: 22846802
Dhrami-Gavazi E, Balaratnasingam C, Lee W, Freund KB (2015) Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration. Int J Retin Vitr 1:15. https://doi.org/10.1186/s40942-015-0015-6
doi: 10.1186/s40942-015-0015-6
Pfau M, Möller PT, Künzel SH, von der Emde L, Lindner M, Thiele S, Dysli C, Nadal J, Schmid M, Schmitz-Valckenberg S, Holz FG, Fleckenstein M (2020) Type 1 choroidal neovascularization is associated with reduced localized progression of atrophy in age-related macular degeneration. Ophthalmol Retina 4(3):238–248. https://doi.org/10.1016/j.oret.2019.09.016